Chandigarh: Covishield is produced in India similar in terms of security and immunogenicity against the English version produced by AstraZeneca.
This has been determined by the results of the 2/3 phase study in the prestigious journal The Lancet Prackrint.
The PAN-India study has 17 centers in this country, which enrolled 1,600 participants.
The study also found that reactogicity – reactions to the vaccine – decreased in the elderly while the immune response was the same in all age groups.
“The reason for the lower reactyity in older adults is unknown but may be consistent with the generally lower inflammatory response seen in this population.
In the AZD1222 (AstraZeneca) study and in the current trial, there are trends for lower reactogitancies After the second dose compared to the first dose, “said research.
This is the result of the first safety and immunogenicity of the covishield of phase 2/3 trials in India.
This vaccine is also non-inferior to AZD1222 (ChadoX1 NCOV-19) in terms of immune responses, concluding research.
In the study of observer-blind, random, controlled, the participants signed up to the immunogenicity cohort and randomized reactogity was assigned to the ratio of 3: 1 to receive covishield or AZD1222.
Participants who enroll in the safety cohort are randomly assigned in the ratio of 3: 1 to receive covishield or placebo.
Of the 1,600, 400 participants were studied for immunogenicity cohorts and reactogenicity, and the rest in the safety cohort.
After two covishield and AZD1222 doses, sero conversion rates (antibody production after infection) for IgG antispike antibodies were 98.0% and 98.9%, while for the first dose of 96.6% and 91.8% respectively .
The efficacy of the covishield vaccine is also considered 81% because the similarity between the vaccine as disclosed in this study.
“Because we did not conduct efficacy studies therefore, we cannot comment on that.
However, given the immune response of the Covishield similar to AstraZeneca, we can consider efficacy with a 12-week loophole between two doses, maybe as good as 81%,” said Prof.
Madhu Gupta, A group of research writers from PGI.
He said, “There are other studies that show the efficacy of the covishield in a tone of more than 95% among HCW in the armed forces.
We also observed a good antibody response after the covishield vaccine at six months, mainly because of the antibodies of the anti-spike IGG.” Oxford University developed Candidate Vaccine, ChadoX1 NCOV-19 (AZD1222), is based on an established platform consisting of Simian Adenovirus Vector ChadoX1 replication deficiency.
AZD1222 has been studied in several clinical trials in countries, including Britain, Brazil and South Africa; All of these studies show vaccine security, and show immunogenicity and high efficacy against Covid-19.
This vaccine was first authorized for emergency use in the UK in December 2020.
Haryana / Punjab / Himachal Study: Covishield similar to England as